- Home
- PRQR vs PBYI Comparison
PRQR vs PBYI Comparison
Compare PRQR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- PBYI
- Stock Information
- Founded
- PRQR 2012
- PBYI 2010
- Country
- PRQR Netherlands
- PBYI United States
- Employees
- PRQR N/A
- PBYI N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- PBYI Health Care
- Exchange
- PRQR Nasdaq
- PBYI Nasdaq
- Market Cap
- PRQR 250.7M
- PBYI 263.4M
- IPO Year
- PRQR 2014
- PBYI N/A
- Fundamental
- Price
- PRQR $2.24
- PBYI $4.91
- Analyst Decision
- PRQR Strong Buy
- PBYI Strong Buy
- Analyst Count
- PRQR 7
- PBYI 1
- Target Price
- PRQR $8.14
- PBYI $7.00
- AVG Volume (30 Days)
- PRQR 600.3K
- PBYI 431.4K
- Earning Date
- PRQR 11-06-2025
- PBYI 11-06-2025
- Dividend Yield
- PRQR N/A
- PBYI N/A
- EPS Growth
- PRQR N/A
- PBYI 434.29
- EPS
- PRQR N/A
- PBYI 0.97
- Revenue
- PRQR $18,859,556.00
- PBYI $238,062,000.00
- Revenue This Year
- PRQR N/A
- PBYI N/A
- Revenue Next Year
- PRQR N/A
- PBYI N/A
- P/E Ratio
- PRQR N/A
- PBYI $5.04
- Revenue Growth
- PRQR N/A
- PBYI 8.63
- 52 Week Low
- PRQR $1.07
- PBYI $2.32
- 52 Week High
- PRQR $4.21
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- PRQR 38.89
- PBYI 45.14
- Support Level
- PRQR $2.61
- PBYI $4.80
- Resistance Level
- PRQR $2.81
- PBYI $5.52
- Average True Range (ATR)
- PRQR 0.22
- PBYI 0.25
- MACD
- PRQR -0.08
- PBYI -0.07
- Stochastic Oscillator
- PRQR 2.27
- PBYI 14.13
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.